BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 27509379)

  • 1. Transfusion Therapy in Children With Sickle Cell Disease.
    Inati A; Mansour AG; Sabbouh T; Amhez G; Hachem A; Abbas HA
    J Pediatr Hematol Oncol; 2017 Mar; 39(2):126-132. PubMed ID: 27509379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
    Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
    Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transfusion therapy for sickle cell disease: a balancing act.
    Chou ST
    Hematology Am Soc Hematol Educ Program; 2013; 2013():439-46. PubMed ID: 24319217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility and efficacy of chronic transfusion for stroke prevention in children with sickle cell disease.
    Mirre E; Brousse V; Berteloot L; Lambot-Juhan K; Verlhac S; Boulat C; Dumont MD; Lenoir G; de Montalembert M
    Eur J Haematol; 2010 Mar; 84(3):259-65. PubMed ID: 19912310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased complications of chronic erythrocytapheresis compared with manual exchange transfusions in children and adolescents with sickle cell disease.
    Woods D; Hayashi RJ; Binkley MM; Sparks GW; Hulbert ML
    Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28544309
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sickle cell disease: time for a closer look at treatment options?
    Sheth S; Licursi M; Bhatia M
    Br J Haematol; 2013 Aug; 162(4):455-64. PubMed ID: 23772687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
    Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
    Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How we manage iron overload in sickle cell patients.
    Coates TD; Wood JC
    Br J Haematol; 2017 Jun; 177(5):703-716. PubMed ID: 28295188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey.
    Vichinsky EP; Ohene-Frempong K;
    Pediatr Hematol Oncol; 2011 Feb; 28(1):37-42. PubMed ID: 20673029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organ iron accumulation in chronically transfused children with sickle cell anaemia: baseline results from the TWiTCH trial.
    Wood JC; Cohen AR; Pressel SL; Aygun B; Imran H; Luchtman-Jones L; Thompson AA; Fuh B; Schultz WH; Davis BR; Ware RE;
    Br J Haematol; 2016 Jan; 172(1):122-30. PubMed ID: 26523836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design of the DREPAGREFFE trial: A prospective controlled multicenter study evaluating the benefit of genoidentical hematopoietic stem cell transplantation over chronic transfusion in sickle cell anemia children detected to be at risk of stroke by transcranial Doppler (NCT 01340404).
    Chevret S; Verlhac S; Ducros-Miralles E; Dalle JH; de Latour RP; de Montalembert M; Benkerrou M; Pondarré C; Thuret I; Guitton C; Lesprit E; Etienne-Julan M; Elana G; Vannier JP; Lutz P; Neven B; Galambrun C; Paillard C; Runel C; Jubert C; Arnaud C; Kamdem A; Brousse V; Missud F; Petras M; Doumdo-Divialle L; Berger C; Fréard F; Taieb O; Drain E; Elmaleh M; Vasile M; Khelif Y; Bernaudin M; Chadebech P; Pirenne F; Socié G; Bernaudin F
    Contemp Clin Trials; 2017 Nov; 62():91-104. PubMed ID: 28821470
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trends in blood transfusion, hydroxyurea use, and iron overload among children with sickle cell disease enrolled in Medicaid, 2004-2019.
    Tang AY; Zhou M; Maillis AN; Lai KW; Lane PA; Snyder AB
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30152. PubMed ID: 36579749
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfusional iron overload in children with sickle cell anemia on chronic transfusion therapy for secondary stroke prevention.
    Kwiatkowski JL; Cohen AR; Garro J; Alvarez O; Nagasubramanian R; Sarnaik S; Thompson A; Woods GM; Schultz W; Mortier N; Lane P; Mueller B; Yovetich N; Ware RE;
    Am J Hematol; 2012 Feb; 87(2):221-3. PubMed ID: 22120913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transfusional iron overload and iron chelation therapy in thalassemia major and sickle cell disease.
    Marsella M; Borgna-Pignatti C
    Hematol Oncol Clin North Am; 2014 Aug; 28(4):703-27, vi. PubMed ID: 25064709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current issues in blood transfusion for sickle cell disease.
    Wahl S; Quirolo KC
    Curr Opin Pediatr; 2009 Feb; 21(1):15-21. PubMed ID: 19242238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
    Greenway A; Ware RE; Thornburg CD
    Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
    Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
    Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of manual chronic partial exchange transfusion in children with sickle disease.
    Aloni MN; Lê PQ; Heijmans C; Huybrechts S; Devalck C; Azzi N; Ngalula-Mujinga M; Ferster A
    Hematology; 2015 Jun; 20(5):284-8. PubMed ID: 25133935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.
    Ware RE; Schultz WH; Yovetich N; Mortier NA; Alvarez O; Hilliard L; Iyer RV; Miller ST; Rogers ZR; Scott JP; Waclawiw M; Helms RW
    Pediatr Blood Cancer; 2011 Dec; 57(6):1011-7. PubMed ID: 21826782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Iron-chelating therapy for transfusional iron overload.
    Solomon LR
    N Engl J Med; 2011 Apr; 364(15):1475-6; author reply 1477. PubMed ID: 21488788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.